Melanoma frontline approach
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) Eric Van Cutsem, MD, PhD University Hospitals Gasthuisberg/Leuven, Leuven,
Frederick National Laboratory for Cancer Research A Plasmid based Reference/Control Strategy for Targeted NGS in Oncology Why Plasmids?: –Addition of alien.
BRF0000320900 Begin with BRAF Searching for a target in metastatic melanoma?
Malignant Melanoma
Molecular & Genomic Pathology in the Management of Cancer: Teaching...Who, When, What and How Antonia R. Sepulveda MD., PhD Columbia University, NY, NY.
